Printer Friendly

KATHLEEN GLAUB JOINS CELL GENESYS AS CHIEF FINANCIAL OFFICER

 FOSTER CITY, Calif., Oct. 8 /PRNewswire/ -- Cell Genesys Inc. (NASDAQ: CEGE) today announced the election of Kathleen Sereda Glaub, 40, to the position of vice president and chief financial officer. R. Scott Greer, 34, the previous chief financial officer, is now concentrating full-time as vice president of corporate development.
 "We are very fortunate to have Kathy Glaub join the Cell Genesys management team, adding her extensive experience in financial management and planning in the biotechnology industry," said Stephen A. Sherwin, M.D., president and chief executive officer. "Moreover, as corporate development plays an increasingly important role in the growth of our business, we are pleased that Scott Greer will be able to focus his talents in that area."
 Glaub's most recent position was treasurer of Genentech Inc., a post she left in 1990. While at Genentech, Glaub was responsible for strategic planning and budgeting; financing; merger and acquisition evaluations; and treasury and finance operations. Before joining Genentech in 1985, Glaub was with Intel Corp. for five years in various finance and treasury management positions.
 Glaub earned a master's degree in accounting and finance from the J.L. Kellogg Graduate School of Management at Northwestern University. She holds a bachelor's degree in psychology from the University of California at Berkeley.
 Greer has been with Cell Genesys since 1991, when he joined the company as vice president of corporate development and chief financial officer after five years with Genetics Institute in corporate development positions.
 Cell Genesys is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products.
 -0- 10/8/93
 /CONTACT: Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys, 415-358-9600, ext. 212/
 (CEGE)


CO: Cell Genesys Inc. ST: California IN: MTC SU: PER

TM-TB -- SF010 -- 0218 10/08/93 14:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1993
Words:352
Previous Article:MARK TWAIN BANCSHARES ANNOUNCES FOURTH QUARTER DIVIDEND
Next Article:TAB ANNOUNCES ACQUISITION OF DATAFILE BUSINESSES IN CANADA, AUSTRALIA AND THE UNITED STATES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters